Tuesday , June 22 2021

[메디파나뉴스]In Tuzeo, EASD demonstrated a patient's glycemic control appropriate to the dose of insulin

Sanofi-aventis Korea announced that its next generation of long-term basal insulin, TJEZO Solostar (ingredient name: insulin glucine, 300 U / ml gene recombination), in the first week of October at the annual European Diabetes Society conference (EASD) The results of the CONTROL study have been published and it has been shown that patients who value their toeose may have a more effective glucose control compared to patients who are adequately dosed under the supervision of a doctor.

According to the TAKE CONTROL study, the number of patients with mean glycosylated hemoglobin (HbA1c) that reached the recommended target of blood glucose of less than 7% was greater in self-adapting patients than in the appropriate patients under the leadership of the primary caretaker. In addition, the patient determined the number of patients who achieved the objective of glucose in the blood without accompanying hypoglycaemia (<3.0 mmol / L) or serious hypoglycaemia (fasting) that required medical support. (67% vs. 58%).

During the study period, the degree of decreased psychological burden was similar in both groups, and the number of patients who reported having a high psychological load after 24 weeks was lower in patients who were dosed properly than those who were in charge 8, 5% vs. 12.2%).

David Russell Jones of the study TAKE CONTROL Professor of diabetes and endocrinology at the Royal Surry County Hospital, University of Surrey, UK "Many diabetics are experiencing hypoglycemia, a major obstacle to adherence to treatment," said the study TAKE CONTROL Insulin Base developed Recently, Tuzeo has been shown to help patients better control their own blood sugar levels. "

Meanwhile, the TAKE CONTROL study was performed in 631 diabetic patients of adult type 2 whose glucose levels were not adequately controlled, with Tozeol for 24 weeks. We compared the efficacy and safety of Tuzeo when the patient administered the dose evaluation and when the person who ordered it was treated.

<© 2018 메디파나뉴스, 무단 전재 및 배포금지>The Center of Korean Medicinal News & # 39; MEDIPANA NEWS

Source link